1 active not recruiting, 1 recruiting, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Withdrawn 1 |
Follow Monitoring: new trials by email Literature Review of Monitoring trials Research Report on Monitoring
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA) Pembrolizumab (200mg), Pembrolizumab (400mg), Monitoring - Metastatic Urothelial Carcinoma | Phase 2 | Withdrawn | Fox Chase Cancer Center | 2023-09-01 | 2023-11-09 | |
| Metformin and Nightly Fasting in Women With Early Breast Cancer Biospecimen Collection, Extended Release Metformin Hydrochloride, Monitoring - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 120 | 2023-04-04 | 2026-01-05 |
Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1)
City of Hope Medical Center (1) · Fox Chase Cancer Center (1) · M.D. Anderson Cancer Center (1)
United States (2) · Italy (1)
Benjamin Miron (1) · Parijatham Thomas, MD (1) · Ravi Salgia, MD (1)
P30CA033572 (1), UG1CA242609 (1)